18 / 23
Page 64
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
T
he American Cancer Society reports that this year there
will be an estimated 600,920 deaths due to cancer in the
United States. Current cancer research includes the use of
biomarkers on the surface of cancer cells to distinguish the
cancerous cells from normal body cells. Molecular cloning
can enhance these biomarkers. Over the past thirty years,
molecular cloning has progressed immensely. From digestion
to plasmid insertion, the possibilities are endless. The AAV
(Adeno Associated Virus) CXCL 12(C-X-C Motif Chemokine
Ligand 12) is a protein coding gene that shows great promise
with cloning and plasmid insertion. Our project aims to
use this gene to bind tightly to biomarkers on the surface
of cancer cells. However, before this optimal binding can
occur, it is essential to know more about the
AAV CXCL 12
gene itself. For this reason, our project includes multiple gel
electrophoresis assays, plasmid insertion/digestion assays
and PCR purification. From the results of these assays, the
efficacy of
AAV CXCL 12
to bind to cancer biomarkers will
become clear. In particular, the cloning assay for the
AAV
CXCL 12
gene holds great potential, as it is possible to clone
extraneous DNA into a different host. If extraneous DNA can
be cloned into a different host, then there is the possibility of
that DNA binding to a biomarker on a cancer cell.
e:
kripa@live.unc.eduMolecular cloning involving AAV-CXCL 12 gene
Kripa Raj Ahuja
University of North Carolina at Chapel Hill, USA